C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in C4 Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +10 vs. Q1 2024
- Shares held
- 60.9M
- +2.67M (+4.6%) vs. Q1 2024
- Total value
- $281.3M
- −$194.2M (−40.8%) vs. Q1 2024
- New holders
- 35
- 32 more added
- Sold out
- 25
- 34 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Sigma Investments, LP | 1,307,733 | $6.04M | 0.01% | +135,893+11.6% | Added |
| Geode Capital Management, LLC | 1,362,216 | $6.29M | 0.00% | +851,901+166.9% | Added |
| Two Sigma Advisers, LP | 1,391,900 | $6.43M | 0.01% | +79,700+6.1% | Added |
| Silverarc Capital Management, LLC | 1,442,841 | $6.67M | 1.65% | +6,910+0.5% | Added |
| OrbiMed Advisors LLC | 1,513,058 | $6.99M | 0.15% | +1,513,058 | New |
| Bank of America Corp | 1,768,499 | $8.17M | 0.00% | −86,659−4.7% | Reduced |
| Balyasny Asset Management LLC | 1,936,139 | $8.94M | 0.02% | −499,241−20.5% | Reduced |
| State Street Corp | 2,994,948 | $13.8M | 0.00% | −4,158,332−58.1% | Reduced |
| Commodore Capital LP | 3,410,384 | $15.8M | 1.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 3,556,699 | $16.4M | 0.00% | +636,671+21.8% | Added |
| Soleus Capital Management, L.P. | 4,051,996 | $18.7M | 1.65% | +1,593,000+64.8% | Added |
| BlackRock Inc. | 4,551,510 | $21.0M | 0.00% | +3,646,504+402.9% | Added |
| Wasatch Advisors Inc | 4,847,150 | $22.4M | 0.12% | +518,671+12.0% | Added |
| Ra Capital Management, L.P. | 4,878,000 | $22.5M | 0.30% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 6,880,527 | $31.8M | 11.47% | +3,245,865+89.3% | Added |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −535,342−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −174,356−100.0% | Sold out |
| BIT Capital GmbH | 0 | $0 | 0.00% | −168,090−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −146,644−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −139,900−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −104,367−100.0% | Sold out |
| Harbor Capital Advisors, Inc. | 0 | $0 | 0.00% | −96,964−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −92,800−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −91,127−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −64,001−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −47,449−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −41,445−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −28,590−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −24,794−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −23,604−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −22,368−100.0% | Sold out |
| Polymer Capital Management (HK) LTD | 0 | $0 | 0.00% | −21,906−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −19,563−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −18,317−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −15,391−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −13,238−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −10,300−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −39−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −4,009−100.0% | Sold out |
| Coston, McIsaac & Partners | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Cutler Group LP | – | – | – | – | Not filed |